Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuwei Kushen add-on therapy in mild-to-moderate ulcerative colitis with inadequate response to 5-ASA
ChiCTR2600131472Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Wuwei Kushen in autoimmune colitis, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Deep remission rate. Started Jan 2026; status: recruiting.
02
Drugs
Wuwei Kushen
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2600131472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131472.